Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MDMA analog is a small molecule serotonin (5-HT) releaser being developed by EQUULUS Therapeutics for the treatment of post-traumatic stress disorder (PTSD). As a psychedelic-inspired therapeutic, it is designed to be non-dissociative and empathy-enhancing, aiming to provide the prosocial and emotional processing benefits of MDMA without the associated neurotoxicity or euphoric effects. The compound is currently in the discovery stage of development and represents a key asset in EQUULUS's mission to develop mainstream CNS therapeutics that address the root causes of psychiatric conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MDMA analog.